---
title: "Lepu Medical: Injection of Recombinant Type A Botulinum Toxin Obtains Drug Clinical Trial Approval Notice"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/251185156.md"
description: "Lepu Medical's subsidiary, Lepu Jiantang Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration to begin clinical trials for injectable recombinant type A botulinum toxin. This product has advantages of low biological risk and high purity, enhancing the company's competitiveness in the dermatology field. However, the project is still in the early stages of research and development, and the clinical trial results carry uncertainties and face the risk of failure"
datetime: "2025-08-01T11:52:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/251185156.md)
  - [en](https://longbridge.com/en/news/251185156.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/251185156.md)
generator: "portal-rs"
---

# Lepu Medical: Injection of Recombinant Type A Botulinum Toxin Obtains Drug Clinical Trial Approval Notice

Lepu Medical announced that its subsidiary Lepu Jiantang Pharmaceutical Co., Ltd. has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for its independently developed injectable recombinant type A botulinum toxin, allowing it to conduct clinical trials. This product has advantages such as low biological risk and high purity, marking the company's excellent and efficient R&D capabilities in the dermatology field, enriching the company's product layout in dermatology, and enhancing its core competitiveness in this segment. However, this research project is still in the early stages of development, and subsequent clinical trials are characterized by high uncertainty in results, significant R&D investment, and long clinical trial cycles, posing a risk of clinical trial failure for the drug

### Related Stocks

- [300003.CN](https://longbridge.com/en/quote/300003.CN.md)

## Related News & Research

- [Jiangsu Yuyue Medical Equipment & Supply: Net profit fell 29.92% year-over-year, but overseas and CGM sales grew sharply](https://longbridge.com/en/news/296602713.md)
- [Delphinus backs NorFalk financing round, taking funding past EUR 5 million](https://longbridge.com/en/news/296751333.md)
- [Grown Rogue outlines planned acquisition of PharmaCann New York cannabis license assets](https://longbridge.com/en/news/296775302.md)
- [09:02 ETIMAGE Skincare Expands Its GLP-1-Targeted Skincare Innovation with New VOL.U.LIFT™ BODY Sculpt + Firm Treatment Complex](https://longbridge.com/en/news/296792631.md)
- [Chromaviso circadian lighting cuts sick leave up to 21%, InnovationsFonden-backed study shows](https://longbridge.com/en/news/296603687.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**